IL17RB and plasma cell myeloma: The therapeutical relevance of CRL4 stems from the finding that immunomodulatory drugs such as thalidomide and its derivatives, which are used for the treatment of multiple myeloma, bind to the CRL4 substrate receptor cereblon (18).